Keywords: مهار کننده فاکتور Xa; Anticoagulants; Asian patients; atrial fibrillation; direct thrombin inhibitors; factor Xa inhibitors;
مقالات ISI مهار کننده فاکتور Xa (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده فاکتور Xa; Atrial fibrillation; Factor Xa inhibitors; Oral anticoagulants; Thrombin inhibitors;
Keywords: مهار کننده فاکتور Xa; Laboratory monitoring; Prothrombin complex concentrates; Specific reversal agents; Factor Xa inhibitors; Direct thrombin inhibitors;
Keywords: مهار کننده فاکتور Xa; Anticoagulation; Reversal of anticoagulation; Warfarin; Vitamin K; Fresh frozen plasma; Prothrombin complex concentrates; Direct thrombin inhibitors; Factor Xa inhibitors;
Keywords: مهار کننده فاکتور Xa; Anticoagulation; Coumadin; Direct thrombin inhibitors; Factor Xa inhibitors; Antiplatelet; Neuraxial; Regional;
Keywords: مهار کننده فاکتور Xa; Apixaban; Dabigatran; Direct thrombin inhibitors; Edoxaban; Factor Xa inhibitors; Rivaroxaban;
Keywords: مهار کننده فاکتور Xa; Dabigatran; Rivaroxaban; Apixaban; Warfarin; Praxbind; Factor Xa inhibitors; Andexanet alfa;
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; Pharmacokinetics; Pharmacodynamics; Administration regimen; Atrial fibrillation; Inhibidores del factor Xa; Farmacocinética; Farmacodinamia; Esquema de administración; Fibrilación auricular;
Keywords: مهار کننده فاکتور Xa; Inhibidores del factor Xa; Farmacocinética; Farmacodinamia; Esquema de administración; Fibrilación auricular; Factor Xa inhibitors; Pharmacokinetics; Pharmacodynamics; Administration regimen; Atrial fibrillation;
Keywords: مهار کننده فاکتور Xa; Antithrombins; Factor Xa inhibitors; Pulmonary embolism; Venous thrombosis;
Keywords: مهار کننده فاکتور Xa; perioperative cardiovascular evaluation; guidelines; VISION study; myocardial injury after noncardiac surgery; troponins; aspirin; clonidine; POISE-2 study; atrial fibrillation; stroke; bleeding; risks scores; dabigatran; factor Xa inhibitors; left atrial
Keywords: مهار کننده فاکتور Xa; Anticoagulation; Novel oral anticoagulants; Atrial fibrillation; Factor IIa inhibitors; Factor Xa inhibitors; Stroke;
Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy
Keywords: مهار کننده فاکتور Xa; Anemia; Anticoagulants; Factor Xa inhibitors; Hemoglobin; Venous thrombosis; Venous thromboembolism;
Are factor Xa inhibitors effective thromboprophylaxis following hip fracture surgery?: A large national database study
Keywords: مهار کننده فاکتور Xa; Hip fracture; Anticoagulation; Deep venous thrombosis; Factor Xa inhibitors;
Clinical conundrums in antithrombotic therapy management: A Delphi Consensus panel
Keywords: مهار کننده فاکتور Xa; AF; atrial fibrillation; PE/VTE; pulmonary embolism and venous thromboembolism; EBM; Evidence Based Medicine; RCT; Randomized Controlled Trial; NOAC; Non-vitamin K antagonist oral anticoagulant; ACS/DES; acute coronary syndrome/drug eluting stent; CHA2DS2
Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective
Keywords: مهار کننده فاکتور Xa; atrial fibrillation; cost-effectiveness; decision-analytic modeling; edoxaban; factor Xa inhibitors; health economics; Markov model; Taiwan; warfarin;
Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Keywords: مهار کننده فاکتور Xa; Anticoagulation; Atrial fibrillation; Direct oral anticoagulant; Edoxaban; Factor Xa inhibitors; Venous thromboembolism;
Design, synthesis and structure-activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; Oxazolidinone derivatives; Anticoagulant activity; Synthesis;
Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; Thromboembolic disorders;
Research ArticleRivaroxaban postmarketing risk of liver injury
Keywords: مهار کننده فاکتور Xa; Rivaroxaban; Drug-induced liver injury; Hepatotoxicity; Adverse drug reactions; Postmarketing; Pharmacovigilance; Anticoagulants; Factor Xa inhibitors; Drug safety;
New Anticoagulants (Dabigatran, Apixaban, Rivaroxaban) for Stroke Prevention in Atrial Fibrillation
Keywords: مهار کننده فاکتور Xa; Anticoagulation; Stroke; Atrial fibrillation; Reversal; Direct thrombin inhibitors; Factor Xa inhibitors; Dabigatran; Rivaroxaban; Apixaban; Edoxaban;
New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials
Keywords: مهار کننده فاکتور Xa; anticoagulants; apixaban; dabigatran; direct thrombin inhibitors; factor Xa inhibitors; rivaroxaban
Dabigatran and Factor Xa Inhibitors for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
Keywords: مهار کننده فاکتور Xa; Atrial fibrillation; cardioembolic stroke; dabigatran; factor Xa inhibitors; stroke
Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature
Keywords: مهار کننده فاکتور Xa; VTE, venous thromboembolism; PE, pulmonary embolism; TKR, total knee replacement; THR, total hip replacement; DVT, deep vein thrombosisanticoagulant therapy; antithrombotic therapy; anticoagulants; direct thrombin inhibitors; factor Xa inhibitors
The promise of novel direct oral anticoagulants
Keywords: مهار کننده فاکتور Xa; thromboembolism; new anticoagulants; direct thrombin inhibitors; factor Xa inhibitors
Chirurgies et actes invasifs chez les patients traités au long cours par un anticoagulant oral anti-IIa ou anti-Xa direct : Propositions du Groupe d’intérêt en hémostase périopératoire (GIHP) et du Groupe d’études sur l’hémostase et la thrombose (GEHT)
Keywords: مهار کننده فاکتور Xa; Chirurgie; Saignements; Thrombose; Anticoagulants oraux; Anti-IIa; Anti-XaSurgery; Bleeding; Thrombosis; Oral anticoagulants; Thrombin; Factor Xa inhibitors
Phenyltriazolinones as potent factor Xa inhibitors
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; Coagulation
Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide} as a clinical candidate
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; Anticoagulation; Structure based design; X-ray analysis
The Thrombin Hypothesis in ACS: A Disappointing Disconnect between Bench Data and Bedside Clinical Trials
Keywords: مهار کننده فاکتور Xa; Acute coronary syndrome; Direct thrombin inhibitors; Factor Xa inhibitors
Oral Xa Inhibitors
Keywords: مهار کننده فاکتور Xa; Oral anticoagulants; Factor Xa inhibitors; Rivaroxaban; Apixaban; Edoxaban; Betrixaban;
A new era for anticoagulants
Keywords: مهار کننده فاکتور Xa; Anticoagulants; Factor Xa inhibitors; Thrombin inhibitors; Venous thromboembolism; Thromboprophylaxis; Orthopedic surgery
Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?
Keywords: مهار کننده فاکتور Xa; Low-molecular-weight heparin; Factor Xa inhibitors; Antithrombin direct inhibitor; Thromboprophylaxis; ThrombosisThrombose; HBPM; Inhibiteurs facteur Xa; Inhibiteur direct de la thrombine; Orthopédie
Highly efficacious factor Xa inhibitors containing α-substituted phenylcycloalkyl P4 moieties
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; α-Substituted phenylcyclopropyls; SAR; Pharmacokinetic; Rabbit arterio-venous shunt
Molecular structure, lipophilicity, solubility, absorption, and polar surface area of novel anticoagulant agents
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; Direct inhibitors of thrombin; Molecular structure; Solvent effect; Lipophilicity; Solubility;
Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: A novel, potent and orally active direct inhibitor of factor Xa
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; Anticoagulant; Non-amidino compound; Oral bioavailability; Protein binding; Lipophilicity
Stereoselective synthesis and biological evaluation of 3,4-diaminocyclohexanecarboxylic acid derivatives as factor Xa inhibitors
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; 3,4-Diaminocyclohexanecarboxylic acid; Stereoselective synthesis
Sulfonamidolactam inhibitors of coagulation factor Xa
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; Anticoagulant; Serine protease inhibitors; Antithrombotic
Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: Discovery of novel, highly potent inhibitors of Factor Xa
Keywords: مهار کننده فاکتور Xa; Alpha-substituted phenylcyclopropyl; Perpendicular conformation; Ortho-substituted biphenyl; Factor Xa inhibitors
Investigation of the terminal P4 domain in a series of d-phenylglycinamide-based factor Xa inhibitors
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; d-Phenylgylcinamides; Antithrombotics;
Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; Cycloalkanediamine; Non-amidine; Anticoagulant
Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; Pyrazole-based; SAR; N-Arylpiperidine;
Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; Enantiopure cyclicdiamine derivatives; SAR; Human liver microsomal stability
SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; (1R,2S)-cycloalkyldiamine derivatives; SAR; X-ray structure
Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; Anticoagulants
Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; Anticoagulants; Antithrombotic agents; Pyrazole; Bicyclic core; Pyrazolo[4,3-d]pyrimidin-7(6H)-ones
Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitors; Anticoagulants; Antithrombotic agents; Pyrazole; Bicyclic core; Pyrazolo[4,3-d]pyrimidin-7(6H)-ones
Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease
Keywords: مهار کننده فاکتور Xa; ACS; acute coronary syndromes; aPTT; activated partial thromboplastin time; Asp189; aspartic acid residue; CAD; coronary artery disease; EDTA; ethylenediaminetetraacetic acid; EPR-1; effector cell protease receptor-1; F; factor; F1.2; fragment 1.2; FEU; f
Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors
Keywords: مهار کننده فاکتور Xa; Serine protease; Factor Xa inhibitors; Antithrombotic agents; 2-Methylbenzofuran; Thiourea; Bioisosteres; N,N′-Disubstituted ketene aminal; 2,2-Dicyanoketene aminal; 2-Nitroketene aminal; Orally active